Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
RegistrantPE PHARMA PTE LTD
Product Classification
D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification
Formulation Information
INJECTION, SUSPENSION
INTRAMUSCULAR
Medical Information
J07BN04
Manufacturer Information
PE PHARMA PTE. LTD.
Siegfried Hameln GmbH
Active Ingredients
SARS-CoV-2 recombinant spike protein (Omicron JN.1)
5 mcg/dose
Documents
Package Inserts
Nuvaxovid Approved PI.pdf
Approved: December 23, 2024
Patient Information Leaflets
Nuvaxovid Approved PIL.pdf
Approved: December 16, 2024